AtriCure (NASDAQ:ATRC – Free Report) had its price objective increased by Oppenheimer from $36.00 to $45.00 in a report issued on Thursday morning,Benzinga reports. They currently have an outperform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback